Effect of Differences in the Expression Levels Steroid Hormone Receptors and HER2 in the Primary Tumor and Metastatic Focus on the Efficacy of Eribulin Monotherapy in Metastatic Breast Cancer
Vol. 69 No. 4 (2023), ORIGINAL ARTICLES. C. CLINICAL RESEARCH
Vol. 69 No. 4 (2023)

Effect of Differences in the Expression Levels Steroid Hormone Receptors and HER2 in the Primary Tumor and Metastatic Focus on the Efficacy of Eribulin Monotherapy in Metastatic Breast Cancer

ORIGINAL ARTICLES. C. CLINICAL RESEARCH
https://doi.org/10.37469/0507-3758-2023-69-4-699-707
Published 02.09.2023
  • Anastasia Stukan+−
  • Roman Murashko
  • Svetlana Kutukova
  • Alla Goryainova
  • Виктория Антипова
Anastasia Stukan
онкодиспансер
https://orcid.org/0000-0002-0698-7710
Roman Murashko
https://orcid.org/0000-0001-8084-8770
Svetlana Kutukova
https://orcid.org/0000-0003-2221-4088
Alla Goryainova
https://orcid.org/0000-0001-7127-7945
Виктория Антипова
https://orcid.org/0000-0002-0006-3306
##article.numberofdownloads## 62
##article.numberofviews## 161
pdf (Русский)

Keywords

Eribulin
estrogen receptor
progesterone receptor
HER2 status

How to Cite

Stukan, A., Murashko , R., Kutukova , S., Goryainova, A., & Антипова, В. (2023). Effect of Differences in the Expression Levels Steroid Hormone Receptors and HER2 in the Primary Tumor and Metastatic Focus on the Efficacy of Eribulin Monotherapy in Metastatic Breast Cancer. Voprosy Onkologii, 69(4), 699–707. https://doi.org/10.37469/0507-3758-2023-69-4-699-707
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

Introduction. Currently, biopsy of metastatic focus is a crucial procedure for personalizing therapy in patients with metastatic breast cancer (mBC). Additionally, there is increasing evidence regarding the predictive and prognostic role of discordance in hormone receptors and human epidermal growth factor receptor 2 (HER2) status in mBC treatment.

Aim. To investigate the influence of variations in steroid hormone receptor and HER2 expression levels in the primary tumor and metastatic focus on the efficacy of Eribulin monotherapy in mBC.

Materials and Methods. The study conducted by the Oncology Department with Thoracic Surgery Course of the Faculty of Advanced Training and Retraining of Specialists of the Kuban State Medical University included patients with mBC (n = 61) who received Eribulin monotherapy at the Clinical Oncology Dispensary No. 1 in Krasnodar, Russia. Clinical data and outcomes were assessed according to medical records and the hospital cancer registry. The role of changes in steroid hormone receptor and HER2 expression in response to Eribulin monotherapy was analyzed.

Results. The study revealed that on Eribulin monotherapy, an ER expression > 50 % in the metastasis reduced progression-free survival (PFS) time (AUC 0.762 ± 0.092, 95 % CI (0.586-0.891), p = 0.0044). A decrease in Eribulin efficacy was observed in cases with HER2-0 the metastasis (AUC 0.750±0.144, 95 % CI (0.578-0.879), p = 0.0833).

PR expression ≤ 20 % (p = 0.0182, OR 0.14, 95 % CI 0.03-0.72) and HER2 3+ status (p = 0.0128) in the metastasis significantly increase PFS. The PFS median in patients with HER2 3+ status was not reached; at HER2-low (1+2+), it was 5 months, at HER2-0, it was 3 months (p = 0.0359, log-rank test). Predictive model decreasing PFS during Eribulin treatment included: ER>90% in the primary tumor, ER > 50 %, PR > 20 %, and HER2-0/low in the metastasis (AUC = 0.614 ± 0.092 (95 % CI 0.510-0.719), p = 0,0289). Thus, a luminal A HER2-negative status was described as an unfavorable surrogate phenotype in the metastatic focus for prescribing Eribulin monotherapy.

Conclusion. The presented data demonstrated the significant prognostic role of the discordance of steroid hormone receptor expression and HER2 status between the primary tumor and metastatic focus in the risk of progression on Eribulin monotherapy. It is evident that biopsy of the metastatic focus is an important factor capable of not only altering the treatment approach regarding the surrogate subtype of the metastatic focus but also personalizing chemotherapy in patients with metastatic breast cancer.

https://doi.org/10.37469/0507-3758-2023-69-4-699-707
##article.numberofdownloads## 62
##article.numberofviews## 161
pdf (Русский)

References

Aurilio G, Disalvatore D, Pruneri G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50:277–89. doi:10.1016/j.ejca.2013.10.004.

Schrijver WA, Suijkerbuijk KP, van Gils CH, et al. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110:568–80. doi:10.1093/jnci/djx273.

Aurilio G, Disalvatore D, Pruneri G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50:277–89. doi:10.1016/j.ejca.2013.10.004.

Dieci MV, Barbieri E, Piacentini F, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol. 2013;24:101–8. doi:10.1093/annonc/mds248.

Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38:1951–62. doi:10.1200/jco.19.02488.

Marchiò C, Annaratone L, Marques A, et al. Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol. 2021;72:123–135. doi:10.1016/j.semcancer.2020.02.016.

Zhang H, Katerji H, Turner BM, et al. HER2-low breast cancers: new opportunities and challenges. Am J Clin Pathol. 2022;157:328–36. doi:10.1093/ajcp/aqab117.

Agostinetto E, Rediti M, Fimereli D, et al. HER2-low breast cancer: Molecular characteristics and prognosis. Cancers. 2021;13:2824. doi:10.3390/cancers13112824.

Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: Pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22:1151–61. doi:10.1016/s1470-2045(21)00301-6.

Zhang H, Katerji H, Turner BM, et al. HER2-low breast cancers: Incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles. Mod Pathol. 2022;35:1075–82. doi:10.1038/s41379-022-01019-5.

Zhang H, Peng Y. Current biological, pathological and clinical landscape of HER2-low breast cancer. Cancers. 2023;15:126. doi:10.3390/cancers15010126.

Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: Pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22:1151–61. doi:10.1016/s1470-2045(21)00301-6.

Tarantino P, Jin Q, Tayob N, et al. Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol. 2022;8:1177–83. doi:10.1001/jamaoncol.2022.2286.

Miglietta F, Griguolo G, Bottosso M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer. 2021;7:137. doi:10.1038/s41523-021-00343-4.

Tarantino P, Gandini S, Nicolò E, et al. Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer. 2022;163:35–43. doi:10.1016/j.ejca.2021.12.022.

Miglietta F, Griguolo G, Bottosso M, et al. HER2-low-positive breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer. 2022;8:66. doi:10.1038/s41523-022-00434-w.

Van den Ende NS, Smid M, Timmermans A, et al. HER2-low breast cancer shows a lower immune response compared to HER2-negative cases. Sci Rep. 2022;12:2974. doi:10.1038/s41598-022-16898-6.

Cortes J, O’Shaughnessy J, Loesch D, et al. EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-923. doi:10.1016/S0140-6736(11)60070-6.

Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594-601. doi:10.1200/JCO.2013.52.4892.

Семиглазов В.Ф., Криворотько П.В., Дашян Г.А., Семиглазова Т.Ю., и др. Клинико-биологическая модель для оценки эффективности системной терапии рака молочной железы. Вопросы онкологии 2018;64(3):289-297 [Semiglazov VF, Krivorotko PV, Dashyan GA, Semiglazova TYu, et al. Clinical and biological model for evaluation of the effectiveness of systemic therapy for breast cancer. Voprosy Onkologii 2018;64(3):289-297 (In Russ.)]. doi:10.37469/0507-3758-2018-64-3-289-297.

Моисеенко Ф.В., Волков Н.М., Богданов А.А., Семиглазов В.Ф., и др. Современные возможности клинического применения экспрессионного типирования опухолей молочной железы. Вопросы онкологии 2016;62(1):31-34 [Moiseenko FV, Volkov NM, Bogdanov AA, Semiglazov VF, et al. Current possibilities of clinical applications of breast tumors typing expression. Voprosy Onkologii 2016;62(1):31-34 (In Russ.)]. doi:10.37469/0507-3758-2016-62-1-31-34.

Twelves C, Kaufman P, Im S, et al. Efficacy of eribulin mesylate inHER2-low or HER2-0 metastatic breast cancer (MBC): results from an analysis of two phase III studies. Presented at 2022 San Antonio Breast Cancer Symposium. San Antonio, TX. 2022. doi:10.1016/j.annonc.2022.03.200.

Kaufman PA, Twelves CJ, Awada AH, et al. 259P Efficacy of eribulin mesylate in HER2-low metastatic breast cancer (MBC): Results from three phase III studies. Annals of Oncology. 2022;33(7):S655-S656. doi:10.1016/j.annonc.2022.07.298.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2023